A Phase 3 interventional study of Azacitidine and Romidepsin in Lymphoma, T-Cell, sponsored by Celgene. Completed at 12 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is a multicentric, open-label, randomized phase 3 trial. The study will be conducted in select countries in Europe and South Korea sponsored by LYSARC and in Japan sponsored by Celgene. There will be a combined enrollment target of 86 randomized patients, with approximately 14 randomized patients from Japan.
The enrollment to the randomized study will start at European sites in parallel to a safety run-in part in Japan. A safety run-in will be conducted to confirm the tolerability of oral azacitidine at doses of 100 mg and 200 mg QD in Asian patients. Once oral azacitidine at 200 mg QD is confirmed as tolerable, Asian patients from Japan and South Korea will start to be randomized into the main study. Additional patients (non-randomized) are anticipated to enroll to the safety run-in.
310 studies on the registry are indexed under Lymphoma, T-Cell; 77 are open to participants now.
This study's enrollment of 93 is above the median of 37 across 270 interventional studies indexed under Lymphoma, T-Cell.
Browse Lymphoma, T-Cell studies →Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted before Celgene became part of Bristol-Myers Squibb.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient had local diagnosed peripheral T cell lymphoma (PTCL) with T-follicular helper (TFH) phenotype according to the criteria of the latest WHO classification based on a surgical lymph node or needle core biopsy including any one of
Local pathology report should be reviewed by the sponsor's medical monitor prior to enrollment.
Meet the following lab criteria:
Female patient of (FCBP) may participate, providing she meets the following conditions:
Have two negative pregnancy tests as verified by the investigator prior to starting study treatment: serum pregnancy test at Screening and negative serum or urine pregnancy test (investigator's discretion) within 72 hours prior to starting treatment with study treatment (Cycle 1 Day 1). She must agree to ongoing pregnancy testing during the study (before beginning each subsequent cycle of treatment), and 28 days after the last study drug administration. This applies even if the patient practices complete abstinence from heterosexual contact.
Agrees to practice true abstinence (which must be reviewed monthly and source documented) or agrees to the use of highly effective methods of from 28 days prior to starting study treatment, and must agree to continue using such precautions during study treatment (including dose interruptions) and for up to 6 months after the last study drug administration. True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, symptomthermal, post ovulation methods) and withdrawal are not acceptable methods of contraception. Cessation of contraception after this point should be discussed with a responsible physician.
Agrees to abstain from breastfeeding during study participation and for at least 6 months after the last study drug administration.
A female of childbearing potential (FCBP) is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months).
Male patient must either practice true abstinence from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agrees to avoid fathering a child, to use highly effective methods of contraception, male condom plus spermicide during sexual contact with a pregnant female or a female of childbearing potential (even if he has undergone a successful vasectomy), from starting dose of IP (cycle 1 Day 1), including dose interruptions through 6 months after receipt of the last study drug administration.
Furthermore, male patient must agree to not give semen or sperm during study drug therapy and for a period of 1 year after end of study drug therapy.
Exclusion Criteria:
Known (HIV) or Virus (HCV) infection, or evidence of active Virus (HBV) infection defined as:
Active other than the one treated in this research. Prior history of malignancies, other than low risk MDS or CMML (with less than 5% blasts in bone marrow), unless the patient has been free of the disease for ≥ 3 years. However, patients with the following history/concurrent conditions are allowed:
Significant active cardiac disease within the previous 6 months, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oral azacytidine 300 mg during 14 first days of 28-days cycle for European (EU) patients, Oral azacytidine 200 mg during 14 first days of 28-days cycle for Asian patients (Treatment until progression, patient decision or toxicity)
Drug: Azacitidine
Romidepsin 14mg/m2 on days 1, 8 and 15 of a 28-days cycle (Treatment until progression, patient decision or toxicity)
Drug: Romidepsin
Gemcitabine 1000mg/m2 on days 1, 8 and 15 of a 28-days cycle (during 6 cycles)
Drug: Gemcitabine
Azacitidine
Also known as: CC-486
Romidepsin
Gemcitabine
Progression Free Survival (PFS) Based on Local Assessment
PFS is defined as the time from randomization into the study to the first observation of documented disease progression (local assessment using Lugano Response Criteria 2014) or death due to any cause, whichever occurs first. If a participant has not progressed or died, PFS will be censored at the time of last visit with adequate assessment. C2 censoring rules were used per US FDA guidance 2015. Progression will be determined as per Response criteria for lymphoma: Lugano classification.
Time frame: From randomization up to documented disease progression or death, whichever occurs first (up to approximately 15 months)
Overall Survival (OS)
Overall survival is defined as the time from the date of randomization to the date of death from any cause. OS was censored at the last date that the participant was known to be alive.
Time frame: From randomization up to the date of death or date last known alive (up to approximately 27 months)
Progression Free Survival (PFS) Based on IRC Assessment
PFS based on Independant Review Committee (IRC) is defined as the time from randomization into the study to the first observation of documented disease progression (reviewed assessment by IRC using Lugano Response Criteria 2014) or death due to any cause. If a patient has not progressed or died, PFS will be censored at the time of last visit with adequate assessment per FDA's guidance 2015 Table C2. Progression will be determined as per Response criteria for lymphoma: Lugano classification.
Time frame: From randomization up to documented disease progression or death, whichever occurs first (up to approximately 37 months)
Overall Response Rates (ORR)
Overall response rates are the percentage of complete response (CR) and partial response (PR) per local assessment. Assessment of response will be based on Lugano Response Criteria 2014 for the radiologic response (CT based), the metabolic response (PET-CT based) and the best response between radiologic and metabolic response. Measurements occurred after Cycle 3, after Cycle 6, and at permanent treatment discontinuation. PR is defined as Score 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size and ≥ 50% decrease in SPD of up to 6 target measurable nodes and extranodal sites. CR is defined as target nodes/nodal masses regressed to ≤ 1.5 cm in LDi, no extralymphatic sites of disease, and Score 1, 2, or 3 with or without a residual mass on the 5 Point Scale. The Lugano 5-point scale is 1, no uptake above background; 2, uptake mediastinum; 3, uptake mediastinum but liver; 4, uptake moderately liver; 5, uptake markedly higher than liver and/or new lesions.
Time frame: Response rate will be measured after Cycle 3, after Cycle 6 (up to approximately 5.5 months)
Complete Response Rate (CRR)
Complete response rate is the percentage of CR (complete metabolic response or CT-based CR) per local assessment before receiving any subsequent anti-lymphoma therapy. Assessment will be based on Lugano Response Criteria 2014 for the radiologic response (CT based), the metabolic response (PET-CT based) and best response between radiologic and metabolic response. Measurements occurred after Cycle 3, Cycle 6, and treatment discontinuation. PR is defined as Score 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size and ≥ 50% decrease in SPD of up to 6 target measurable nodes and extranodal sites. CR is defined as target nodes/nodal masses regressed to ≤ 1.5 cm in LDi, no extralymphatic sites of disease, and Score 1, 2, or 3 with or without a residual mass. The Lugano 5-point scale is 1, no uptake above background; 2, uptake mediastinum; 3, uptake mediastinum but liver; 4, uptake moderately liver; 5, uptake markedly higher than liver and/or new lesions.
Time frame: Response rate will be measured after Cycle 3, after Cycle 6 (up to approximately 5.5 months)
Duration of Response (DOR)
Duration of response is defined as the time from attainment of complete response (CR) or partial response (PR) per local assessment to the date of first documented disease progression, relapse (local assessment) or death from any cause. Participants alive and free of progression will be censored at their last visit with adequate assessment.CR: complete metabolic response or computed tomography (CT)-based CR; PR: partial metabolic response or CT-based PR before subsequent anti-lymphoma therapy.
Time frame: From randomization to the date of first documented disease progression, relapse (local assessment) or death from any cause (up to approximately 27 months)
Time to Response (TTR)
Time to response is defined as the time from randomization to the date of attainment of complete response (CR) or partial response (PR) per local assessment until end of treatment. If a participant is not responder, time to response will be censored at the time of last visit with adequate assessment. CR: complete metabolic response or computed tomography (CT)-based CR; PR: partial metabolic response or CT-based PR before subsequent anti-lymphoma therapy.
Time frame: From randomization to the date of attainment of complete response (CR) or partial response (PR) until end of treatment (up to approximately 37 months)
Progression Free Survival 2 (PFS2) on Local Assessment
PFS2 based on local assessment is defined as the time from randomization to objective tumor progression on next-line treatment or death from any cause. Participants without next-line therapy who did not die and participants who did not relapse or not die after next-line therapy will be censored at the last adequate tumor assessment date.
Time frame: From randomization to objective tumor progression on next-line treatment or death from any cause (up to approximately 27 months)
Mean Change in Minimal Important Differences (MIDs) of the EORTC QLQ-C30 Health-related Quality-of-Life Domain Scores
The minimal important difference (MID) is the size of difference in Quality-of-Life score that is considered relevant (i.e. warranting a change in treatment or examinations). The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQC30) subscale values are the lower threshold for MID over time, based on within-group mean change. QLQ-C30 has 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain), a global health status / quality of life (QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). Each scale was scored on a range from 0 to 100. Higher scores represent a higher response level. Note that a high score for global health status or for a functional scale represents a high or healthy level of functioning, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
Time frame: At baseline and on Day 1 of each cycle up to treatment discontinuation (up to approximately 27 months)
| Milestone | Oral Azacitidine | Investigators Choice Therapy - Romidepsin | Investigators Choice Therapy - Bendamustine | Investigators Choice Therapy - Gemcitabine |
|---|---|---|---|---|
| Started | 7 | 0 | 0 | 0 |
| Completed | 7 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Oral Azacitidine | Investigators Choice Therapy - Romidepsin | Investigators Choice Therapy - Bendamustine | Investigators Choice Therapy - Gemcitabine |
|---|---|---|---|---|
| Started | 49 | 4 | 16 | 24 |
| Safety run-in | 7 | 0 | 0 | 0 |
| Completed | 42 | 4 | 16 | 23 |
| Not completed | 7 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Completed safety run-in treatment | 7 | 0 | 0 | 0 |
| Milestone | Oral Azacitidine | Investigators Choice Therapy - Romidepsin | Investigators Choice Therapy - Bendamustine | Investigators Choice Therapy - Gemcitabine |
|---|---|---|---|---|
| Started | 42 | 4 | 16 | 23 |
| Completed | 0 | 0 | 4 | 5 |
| Not completed | 42 | 4 | 12 | 18 |
| Withdrew: Other reasons | 0 | 1 | 0 | 3 |
| Withdrew: Consent withdrawal | 0 | 0 | 0 | 1 |
| Withdrew: Death | 1 | 0 | 1 | 2 |
| Withdrew: Toxicity of study treatment | 2 | 0 | 4 | 1 |
| Withdrew: Progression | 32 | 1 | 7 | 11 |
| Withdrew: Completed treatment | 7 | 2 | 0 | 0 |
PFS is defined as the time from randomization into the study to the first observation of documented disease progression (local assessment using Lugano Response Criteria 2014) or death due to any cause, whichever occurs first. If a participant has not progressed or died, PFS will be censored at the time of last visit with adequate assessment. C2 censoring rules were used per US FDA guidance 2015. Progression will be determined as per Response criteria for lymphoma: Lugano classification.
| Months | Oral Azacitidine | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) |
|---|---|---|
| Progression Free Survival (PFS) Based on Local Assessment | 5.6 (2.66 to 7.26) | 2.8 (1.87 to 4.83) |
Overall survival is defined as the time from the date of randomization to the date of death from any cause. OS was censored at the last date that the participant was known to be alive.
| Months | Oral Azacitidine | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) |
|---|---|---|
| Overall Survival (OS) | 18.4 (12.88 to 31.47) | 10.3 (4.24 to 13.50) |
PFS based on Independant Review Committee (IRC) is defined as the time from randomization into the study to the first observation of documented disease progression (reviewed assessment by IRC using Lugano Response Criteria 2014) or death due to any cause. If a patient has not progressed or died, PFS will be censored at the time of last visit with adequate assessment per FDA's guidance 2015 Table C2. Progression will be determined as per Response criteria for lymphoma: Lugano classification.
| Months | Oral Azacitidine | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) |
|---|---|---|
| Progression Free Survival (PFS) Based on IRC Assessment | 4.2 (2.66 to 5.88) | 3.2 (2.10 to 4.83) |
Overall response rates are the percentage of complete response (CR) and partial response (PR) per local assessment. Assessment of response will be based on Lugano Response Criteria 2014 for the radiologic response (CT based), the metabolic response (PET-CT based) and the best response between radiologic and metabolic response. Measurements occurred after Cycle 3, after Cycle 6, and at permanent treatment discontinuation. PR is defined as Score 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size and ≥ 50% decrease in SPD of up to 6 target measurable nodes and extranodal sites. CR is defined as target nodes/nodal masses regressed to ≤ 1.5 cm in LDi, no extralymphatic sites of disease, and Score 1, 2, or 3 with or without a residual mass on the 5 Point Scale. The Lugano 5-point scale is 1, no uptake above background; 2, uptake mediastinum; 3, uptake mediastinum but liver; 4, uptake moderately liver; 5, uptake markedly higher than liver and/or new lesions.
| Percentage of participants | Oral Azacitidine | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) |
|---|---|---|
| Cycle 3 | 33.3 (19.6 to 49.5) | 43.2 (28.3 to 59.0) |
| Cycle 6 | 31.0 (17.6 to 47.1) | 22.7 (11.5 to 37.8) |
Complete response rate is the percentage of CR (complete metabolic response or CT-based CR) per local assessment before receiving any subsequent anti-lymphoma therapy. Assessment will be based on Lugano Response Criteria 2014 for the radiologic response (CT based), the metabolic response (PET-CT based) and best response between radiologic and metabolic response. Measurements occurred after Cycle 3, Cycle 6, and treatment discontinuation. PR is defined as Score 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size and ≥ 50% decrease in SPD of up to 6 target measurable nodes and extranodal sites. CR is defined as target nodes/nodal masses regressed to ≤ 1.5 cm in LDi, no extralymphatic sites of disease, and Score 1, 2, or 3 with or without a residual mass. The Lugano 5-point scale is 1, no uptake above background; 2, uptake mediastinum; 3, uptake mediastinum but liver; 4, uptake moderately liver; 5, uptake markedly higher than liver and/or new lesions.
| Percentage of participants | Oral Azacitidine | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) |
|---|---|---|
| Cycle 3 | 11.9 (4.0 to 25.6) | 22.7 (11.5 to 37.8) |
| Cycle 6 | 11.9 (4.0 to 25.6) | 15.9 (6.6 to 30.1) |
Duration of response is defined as the time from attainment of complete response (CR) or partial response (PR) per local assessment to the date of first documented disease progression, relapse (local assessment) or death from any cause. Participants alive and free of progression will be censored at their last visit with adequate assessment.CR: complete metabolic response or computed tomography (CT)-based CR; PR: partial metabolic response or CT-based PR before subsequent anti-lymphoma therapy.
| Percentage of participants | Oral Azacitidine | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) |
|---|---|---|
| Duration of Response (DOR) | 10.4 (2.56 to NA) | 3.4 (2.00 to NA) |
Time to response is defined as the time from randomization to the date of attainment of complete response (CR) or partial response (PR) per local assessment until end of treatment. If a participant is not responder, time to response will be censored at the time of last visit with adequate assessment. CR: complete metabolic response or computed tomography (CT)-based CR; PR: partial metabolic response or CT-based PR before subsequent anti-lymphoma therapy.
| Months | Oral Azacitidine | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) |
|---|---|---|
| Time to Response (TTR) | 3 (3 to 6) | 2.7 (1 to 4) |
PFS2 based on local assessment is defined as the time from randomization to objective tumor progression on next-line treatment or death from any cause. Participants without next-line therapy who did not die and participants who did not relapse or not die after next-line therapy will be censored at the last adequate tumor assessment date.
| Months | Oral Azacitidine | Investigators Choice Therapy Combined (Romidepsin, Bendamustine, Gemcitabine) |
|---|---|---|
| Progression Free Survival 2 (PFS2) on Local Assessment | 11.0 (6.44 to 18.89) | 6.7 (3.52 to 9.56) |
The minimal important difference (MID) is the size of difference in Quality-of-Life score that is considered relevant (i.e. warranting a change in treatment or examinations). The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQC30) subscale values are the lower threshold for MID over time, based on within-group mean change. QLQ-C30 has 5 functional scales (physical, role, emotional, cognitive, social), 3 symptom scales (fatigue, nausea/vomiting, pain), a global health status / quality of life (QoL) scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). Each scale was scored on a range from 0 to 100. Higher scores represent a higher response level. Note that a high score for global health status or for a functional scale represents a high or healthy level of functioning, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
Results for this outcome have not been posted.
Collected over Participants were assessed for all-cause mortality from their enrollment to study completion, (up to approximately 37 months). SAEs and Other AEs were assessed from first dose to 28 days following last dose (up to approximately 38 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Azacitidine: 200 mg | 6/8 (75%) | 2/8 (25%) | 7/8 (87.5%) |
| Oral Azacitidine: 300 mg | 20/34 (58.8%) | 9/34 (26.5%) | 33/34 (97.1%) |
| Investigators Choice Therapy - Romidepsin | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| Investigators Choice Therapy - Bendamustine | 13/16 (81.3%) | 8/16 (50%) | 16/16 (100%) |
| Investigators Choice Therapy - Gemcitabine: 1000 mg/m2 | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) |
| Investigators Choice Therapy - Gemcitabine: 1200 mg/m2 | 14/21 (66.7%) | 9/20 (45%) | 19/20 (95%) |
| Safety Run-in Oral Azacitidine: 100 mg | 1/4 (25%) | 0/3 (0%) | 3/3 (100%) |
| Safety Run-in Oral Azacitidine: 200 mg | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Oral Azacitidine: 200 mg | Oral Azacitidine: 300 mg | Investigators Choice Therapy - Romidepsin | Investigators Choice Therapy - Bendamustine | Investigators Choice Therapy - Gemcitabine: 1000 mg/m2 | Investigators Choice Therapy - Gemcitabine: 1200 mg/m2 | Safety Run-in Oral Azacitidine: 100 mg | Safety Run-in Oral Azacitidine: 200 mg |
|---|---|---|---|---|---|---|---|---|
| Acute coronary syndromeCardiac disorders | 0/8 | 0/34 | 0/4 | 0/16 | 0/3 | 0/20 | 0/3 | 1/3 |
| Epstein-Barr virus infection reactivationInfections and infestations | 1/8 | 1/34 | 1/4 | 1/16 | 0/3 | 0/20 | 0/3 | 0/3 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 0/34 | 1/4 | 0/16 | 0/3 | 0/20 | 0/3 | 0/3 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/8 | 0/34 | 1/4 | 0/16 | 0/3 | 0/20 | 0/3 | 0/3 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/8 | 0/34 | 0/4 | 3/16 | 0/3 | 0/20 | 0/3 | 0/3 |
| Systemic candidaInfections and infestations | 1/8 | 0/34 | 0/4 | 0/16 | 0/3 | 0/20 | 0/3 | 0/3 |
| Epstein-Barr virus associated lymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/8 | 0/34 | 0/4 | 0/16 | 0/3 | 0/20 | 0/3 | 0/3 |
| Cardiac failureCardiac disorders | 0/8 | 1/34 | 0/4 | 0/16 | 0/3 | 2/20 | 0/3 | 0/3 |
| CellulitisInfections and infestations | 0/8 | 0/34 | 0/4 | 0/16 | 0/3 | 2/20 | 0/3 | 0/3 |
| InfectionInfections and infestations | 0/8 | 0/34 | 0/4 | 0/16 | 0/3 | 2/20 | 0/3 | 0/3 |
| Event | Oral Azacitidine: 200 mg | Oral Azacitidine: 300 mg | Investigators Choice Therapy - Romidepsin | Investigators Choice Therapy - Bendamustine | Investigators Choice Therapy - Gemcitabine: 1000 mg/m2 | Investigators Choice Therapy - Gemcitabine: 1200 mg/m2 | Safety Run-in Oral Azacitidine: 100 mg | Safety Run-in Oral Azacitidine: 200 mg |
|---|---|---|---|---|---|---|---|---|
| LeukopeniaBlood and lymphatic system disorders | 0/8 | 0/34 | 0/4 | 1/16 | 3/3 | 1/20 | 1/3 | 1/3 |
| LymphopeniaBlood and lymphatic system disorders | 5/8 | 15/34 | 3/4 | 14/16 | 3/3 | 15/20 | 0/3 | 2/3 |
| ThrombocytopeniaBlood and lymphatic system disorders | 3/8 | 7/34 | 4/4 | 7/16 | 2/3 | 8/20 | 1/3 | 1/3 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 9/34 | 1/4 | 1/16 | 0/3 | 5/20 | 0/3 | 3/3 |
| VomitingGastrointestinal disorders | 4/8 | 14/34 | 1/4 | 2/16 | 0/3 | 1/20 | 1/3 | 3/3 |
| NeutropeniaBlood and lymphatic system disorders | 3/8 | 15/34 | 3/4 | 9/16 | 2/3 | 11/20 | 1/3 | 2/3 |
| NauseaGastrointestinal disorders | 5/8 | 17/34 | 2/4 | 5/16 | 0/3 | 6/20 | 0/3 | 0/3 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/8 | 0/34 | 2/4 | 0/16 | 0/3 | 0/20 | 0/3 | 0/3 |
| StomatitisGastrointestinal disorders | 1/8 | 0/34 | 2/4 | 0/16 | 0/3 | 0/20 | 0/3 | 0/3 |
| AnaemiaBlood and lymphatic system disorders | 3/8 | 10/34 | 1/4 | 2/16 | 1/3 | 9/20 | 0/3 | 1/3 |
| Age, Continuous(Years) | Oral Azacitidine | Investigators Choice Therapy - Romidepsin | Investigators Choice Therapy - Bendamustine | Investigators Choice Therapy - Gemcitabine | Total |
|---|---|---|---|---|---|
| Mean | 69.3 ± 9.28 | 67.0 ± 7.16 | 60.8 ± 9.90 | 69.4 ± 10.80 | 67.8 ± 10.11 |
| Sex: Female, Male(Participants) | Oral Azacitidine | Investigators Choice Therapy - Romidepsin | Investigators Choice Therapy - Bendamustine | Investigators Choice Therapy - Gemcitabine | Total |
|---|---|---|---|---|---|
| Female | 22 | 1 | 6 | 9 | 38 |
| Male | 27 | 3 | 10 | 15 | 55 |
| Race (NIH/OMB)(Participants) | Oral Azacitidine | Investigators Choice Therapy - Romidepsin | Investigators Choice Therapy - Bendamustine | Investigators Choice Therapy - Gemcitabine | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Oral Azacitidine | Investigators Choice Therapy - Romidepsin | Investigators Choice Therapy - Bendamustine | Investigators Choice Therapy - Gemcitabine | Total |
|---|---|---|---|---|---|
| Asia | 15 | 4 | 0 | 3 | 22 |
| Europe | 34 | 0 | 16 | 21 | 71 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Ran from Nov 2018 to primary completion in Feb 2021, 27 months.
Results were first posted in Jul 2024, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Azacitidine